John D. Fryer

Dr. John D. Fryer is a Professor and the inaugural Director of the Center for Accelerated Nanotherapeutics at the Translational Genomics Research Institute (TGen) within the Bioinnovation and Genome Sciences Division. His research focuses on translational neuroscience with emphasis on Alzheimer's disease and related dementias, neuroinflammation mechanisms, and development of novel biologics including nanobodies and picobodies.

Dr. Fryer's laboratory pursues NIH-funded research at the intersection of genetics, aging, and neuroinflammation. His work spans multiple critical areas of neuroscience including:

• Alzheimer's disease and related dementias, particularly the inflammatory aspects of neurodegeneration
• Nanobody and picobody development for therapeutic targeting of disease-critical proteins
• Sepsis and acute inflammation and their impact on brain function in aged individuals
• Psilocybin and mood disorders, studying differential brain responses to micro- versus macro-dosing
• Brain tumor interactions with the immune system and neurons, including the intriguing inverse relationship between Alzheimer's disease and brain tumor susceptibility

Analysis of Dr. Fryer's publication record reveals a strong focus on APOE variants, microglial responses in neurodegeneration, and innovative biologics development. His research increasingly integrates multi-omic approaches including single-cell RNA sequencing and spatial transcriptomics to uncover novel therapeutic targets. His lab has developed searchable databases like www.fryerlab.com/ribotag and https://fryerlab.shinyapps.io/LBD_CWOW/ to share research data with the scientific community.

Dr. Fryer has published extensively in high-impact journals including Nature Immunology, Nature Neuroscience, Science Translational Medicine, Science, and Neuron. His recent work on nanobody development for targeting Alzheimer's pathology represents a promising translational approach with potential clinical applications.

His laboratory maintains active collaborations, as evidenced by the extensive co-author networks in his publications, and continues to secure NIH funding for innovative neuroscience research addressing critical challenges in neurodegenerative disease, brain inflammation, and novel therapeutic development.